Datroway approved in the U.S. for patients with previously treated metastatic HR Positive, HER2 negative breast cancer – Daiichi Sankyo
Datroway (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC… read more.